Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Being specific about race-specific medicine.

Kahn J, Sankar P.

Health Aff (Millwood). 2006 Sep-Oct;25(5):w375-7. Epub 2006 Aug 15.

2.

BiDil: from another vantage point.

Puckrein G.

Health Aff (Millwood). 2006 Sep-Oct;25(5):w368-74. Epub 2006 Aug 15.

3.

Food & Drug Administration panel approves heart failure medication aimed at African-Americans.

[No authors listed]

Pharmacogenomics. 2005 Jul;6(5):455. No abstract available.

PMID:
16705760
4.

Bidil: recontextualizing the race debate.

S├ęguin B, Hardy B, Singer PA, Daar AS.

Pharmacogenomics J. 2008 Jun;8(3):169-73. doi: 10.1038/sj.tpj.6500489. Epub 2008 Jan 15. No abstract available.

PMID:
18195727
5.

The paradox of race in the Bidil debate.

Crawley L.

J Natl Med Assoc. 2007 Jul;99(7):821-2. No abstract available.

6.

Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients.

Ellison GT, Kaufman JS, Head RF, Martin PA, Kahn JD.

J Law Med Ethics. 2008 Fall;36(3):449-57. doi: 10.1111/j.1748-720X.2008.290.x.

7.

Misreading race and genomics after BiDil.

Kahn J.

Nat Genet. 2005 Jul;37(7):655-6. No abstract available.

PMID:
15990879
8.

"Special treatment": BiDil, Tuskegee, and the logic of race.

Reverby SM.

J Law Med Ethics. 2008 Fall;36(3):478-84. doi: 10.1111/j.1748-720X.2008.294.x.

PMID:
18840239
9.

BiDil: false promises: faulty statistics and reasoning have lead to the first "racial medicine".

Kahn J.

Genewatch. 2005 Nov-Dec;18(6):6-9, 18. No abstract available.

PMID:
16459407
10.

Illuminating BiDil.

[No authors listed]

Nat Biotechnol. 2005 Aug;23(8):903. No abstract available.

PMID:
16082345
12.

Race, pharmacogenomics, and marketing: putting BiDil in context.

Kahn J.

Am J Bioeth. 2006 Sep-Oct;6(5):W1-5.

PMID:
16997802
13.

U.S. to review drug intended for one race.

Saul S.

N Y Times Web. 2005 Jun 13:A1, A15. No abstract available.

PMID:
15966118
14.

Race-based therapeutics.

Bloche MG.

N Engl J Med. 2004 Nov 11;351(20):2035-7. Epub 2004 Nov 8. No abstract available.

15.

FDA approves heart drug for black patients.

Meadows M.

FDA Consum. 2005 Sep-Oct;39(5):8-9.

16.

BiDil for heart failure in black patients.

Kahn JD.

Ann Intern Med. 2007 Aug 7;147(3):215; author reply 215-6. No abstract available.

PMID:
17679713
17.

BiDil for heart failure in black patients.

Bibbins-Domingo K, Fernandez A.

Ann Intern Med. 2007 Aug 7;147(3):214-5; author reply 215-6. No abstract available.

PMID:
17679712
18.

BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.

Temple R, Stockbridge NL.

Ann Intern Med. 2007 Jan 2;146(1):57-62.

PMID:
17200223
19.

What's right (and wrong) with racially stratified research and therapies.

Sade RM.

J Natl Med Assoc. 2007 Jun;99(6):693-6. No abstract available.

20.

"Ethnic drugs".

Kahn J.

Hastings Cent Rep. 2005 Jan-Feb;35(1):1 p following 48. No abstract available.

PMID:
15799501
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk